Purinergic-Glycinergic Interaction in Neurodegenerative and Neuroinflammatory Disorders of the Retina

Int J Mol Sci. 2021 Jun 8;22(12):6209. doi: 10.3390/ijms22126209.

Abstract

Neurodegenerative-neuroinflammatory disorders of the retina seriously hamper human vision. In searching for key factors that contribute to the development of these pathologies, we considered potential interactions among purinergic neuromodulation, glycinergic neurotransmission, and microglia activity in the retina. Energy deprivation at cellular levels is mainly due to impaired blood circulation leading to increased release of ATP and adenosine as well as glutamate and glycine. Interactions between these modulators and neurotransmitters are manifold. First, P2Y purinoceptor agonists facilitate reuptake of glycine by glycine transporter 1, while its inhibitors reduce reverse-mode operation; these events may lower extracellular glycine levels. The consequential changes in extracellular glycine concentration can lead to parallel changes in the activity of NR1/NR2B type NMDA receptors of which glycine is a mandatory agonist, and thereby may reduce neurodegenerative events in the retina. Second, P2Y purinoceptor agonists and glycine transporter 1 inhibitors may indirectly inhibit microglia activity by decreasing neuronal or glial glycine release in energy-compromised retina. These inhibitions may have a role in microglia activation, which is present during development and progression of neurodegenerative disorders such as glaucomatous and diabetic retinopathies and age-related macular degeneration or loss of retinal neurons caused by thromboembolic events. We have hypothesized that glycine transporter 1 inhibitors and P2Y purinoceptor agonists may have therapeutic importance in neurodegenerative-neuroinflammatory disorders of the retina by decreasing NR1/NR2B NMDA receptor activity and production and release of a series of proinflammatory cytokines from microglial cells.

Keywords: glycine transporters; glycinergic neurotransmission; microglia; neurodegeneration; neuroinflammation; purinergic modulation; retina.

Publication types

  • Review

MeSH terms

  • Animals
  • Glycine Agents / metabolism*
  • Humans
  • Inflammation / complications
  • Inflammation / metabolism
  • Inflammation / pathology*
  • Neurodegenerative Diseases / complications
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / pathology*
  • Neurons / metabolism
  • Neurons / pathology*
  • Receptors, Purinergic / metabolism*
  • Retinal Diseases / complications
  • Retinal Diseases / metabolism
  • Retinal Diseases / pathology*

Substances

  • Glycine Agents
  • Receptors, Purinergic